- Home
- AKAN vs SLRX Comparison
AKAN vs SLRX Comparison
Compare AKAN & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKAN | SLRX |
|---|---|---|
| Founded | 2021 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 3.6M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | AKAN | SLRX |
|---|---|---|
| Price | $0.92 | $0.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.5M | 660.6K |
| Earning Date | 12-23-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $836,664.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 183.67 | N/A |
| 52 Week Low | $0.74 | $0.71 |
| 52 Week High | $9.29 | $108.00 |
Technical Indicators
Market Signals| Indicator | AKAN | SLRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 26.09 |
| Support Level | $0.74 | $0.81 |
| Resistance Level | $1.34 | $0.89 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 28.67 | 0.00 |
Price Performance
Historical ComparisonAbout AKAN Akanda Corp.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.